00013.HK
HUTCHMED (China) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 21.54
−1.19%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 22.00
From 52W high−23.07%
Volume6.69M
Market capHKD 18.49B
P/E (TTM)148.4x
P/S (TTM)4.3x
Div yield—
Key dataSep 18, 2026
Open
HKD 22.00
From 52W high
−23.07%
Volume
6.69M
Market cap
HKD 18.49B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−53.1x
P/E (TTM)
148.4x
RSI (14)
58.2
MomentumView details →
1D Return
−1.19%
YTD Return
+4.46%
Similar companies
Latest newsMore news →
Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.18d agoChina's National Medical Products Administration approved HUTCHMED's ATLED (fanregratinib) for the treatment of patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.24d agoHUTCHMED announced that its registrational Phase 2 trial of Fanregratinib met the primary endpoint in bile duct cancer, and its New Drug Application for the drug was accepted for review and granted priority.88d ago